479552-71-1

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-1-[(4-methylphenyl)sulfonyl]-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-1-[(4-methylphenyl)sulfonyl]-;5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine;1H-Pyrrolo[2,3-B]Pyridine, 5-Bromo-1-[(4-Methylphenyl)Sulfonyl]-(WX636112)
• CAS NO: 479552-71-1
• Molecular Formula: C₁₄H₁₁BrN₂O₂S
• Molecular Weight: 351.22
• Mol File: 479552-71-1.mol

Chemical Properties

• Boiling Point: 498.34°C at 760 mmHg
• Flash Point: 255.187°C
• Appearance: /
• Density: 1.597g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.684
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-1-[(4-methylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-1-[(4-methylphenyl)sulfonyl]-(479552-71-1)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 5-bromo-1-[(4-methylphenyl)sulfonyl]-(479552-71-1)

Safety Data

• Hazardous Substances Data: 479552-71-1(Hazardous Substances Data)

Usage

Chemical class

pyrrolopyridine derivatives
A class of heterocyclic organic compounds containing a pyrrolidine and pyridine ring.

Main structure

1H-Pyrrolo[2,3-b]pyridine
A heterocyclic organic compound consisting of a fused pyrrolidine and pyridine ring.

Functional groups

5-bromo and (4-methylphenyl)sulfonyl

5-bromo

A bromine atom attached to the pyridine ring, enhancing the compound's reactivity and versatility.

(4-methylphenyl)sulfonyl

A sulfonyl group connected to a 4-methylphenyl ring, contributing to the compound's potential applications in pharmaceutical and agrochemical synthesis.

Versatility

Building block for synthesis
The presence of bromine and sulfonyl groups makes the compound a valuable building block for creating various pharmaceutical and agrochemical compounds.

Potential applications

Drug development and intermediate in organic synthesis
The compound has potential applications in the development of new drugs and can be used as an intermediate for producing other bioactive molecules.

Unique structure and functional groups

Valuable tool for research
The compound's unique structure and functional groups make it a valuable tool for both medicinal and chemical research.

InChI:InChI=1/C14H11BrN2O2S/c1-10-2-4-13(5-3-10)20(18,19)17-7-6-11-8-12(15)9-16-14(11)17/h2-9H,1H3

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 849067-95-4 1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 849069-60-9 1-(toluene-4-sulfonyl)-5-vinyl-1H-pyrrolo[2,3-b]pyridine 
• 348640-93-7 5-phenyl-1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine 
• 1036028-15-5 5-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1204400-80-5 5-[1-(toluene-4-sulphonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-thiophene-2-carbonitrile 

Relevant articles and documents

AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS

Provided herein are compounds of Formula (I) and Formula (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

Small molecular compound for inhibiting activity of AKT and STAT3 and application of small molecular compound

The invention provides a small molecular compound for inhibiting the activity of AKT and STAT3 and an application of the small molecular compound. The structure of the small molecular compound is shown as a compound f-5. The small molecular compound f-5 p

Synthesis of Differentially Protected Azatryptophan Analogs via Pd2(dba)3/XPhos Catalyzed Negishi Coupling of N-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected tert-Butyl (R)-2-Amino-3-iodopropanoate

Unnatural amino acids play an important role in peptide based drug discovery. Herein, we report a class of differentially protected azatryptophan derivatives synthesized from N-tosyl-3-haloazaindoles 1 and Fmoc-protected tert-butyl iodoalanine 2 via a Neg

Synthesis and Photophysical Characterization of Azoheteroarenes

A set of azoheteroarenes have been synthesized with Buchwald-Hartwig coupling and microwave-assisted O2 oxidation as the key steps. Several compounds exhibit good to excellent photoswitching properties (high switching efficiency, good fatigue r

AZAINDOLES AS INHIBITORS OF HPK1

Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1- dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma

The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC50 ≤ 50 nM) significantly decreased viability, clonogenic survival, migration, and invasion of glioblastoma cells. Target engagement was confirmed with genetic knockdown and the cellular thermal shift assay. We demonstrate that DYRK1A’s thermal stability in cells is increased upon compound treatment, confirming binding in cells. In summary, we present synthesis, structure-activity relationship, and efficacy in glioblastoma-relevant models for a library of novel 7-azaindoles.

NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7

The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.